Company Update

Viropro has signed a non-binding Letter of Intent for the acquisition of NovaRx, a San Diego based pioneer in immuno-oncology, in an all-stock transaction that is expected to close by year-end, subject to the approval by both companies of definitive documents and the achievement of certain other milestones. 

 

The Letter of Intent is non-binding and may be terminated by either party based on failure to comply with its terms or upon 30 days written notice by either party.

 

Watch for updates here and on our new web site -- coming soon

Print Print | Sitemap
© VIROPRO